raynaud disease

Summary

Alias: raynaud phenomenon, raynauds disease
Summary: An idiopathic vascular disorder characterized by bilateral Raynaud phenomenon, the abrupt onset of digital paleness or CYANOSIS in response to cold exposure or STRESS.

Webpages

  1. research - division of rheumatology and clinical immunology at the university of pittsburgh department of medicine
    www.dept-med.pitt.edu/Rheum/research.html
  2. scleroderma
    www.chw.org/display/PPF/DocID/21658/router.asp
  3. scleroderma
    www.chw.org/display/PPF/DocID/21658/router.asp#1658
  4. scleroderma
    www.childrens.com/HealthLibrary/HealthLibContent.cfm?pageid= ...
  5. scleroderma program: classification of scleroderma
    www.med.umich.edu/scleroderma/patients/classification.htm
  6. retnet: disease table
    www.sph.uth.tmc.edu/retnet/disease.htm
  7. our physicians - health information
    www.memorialhealth.com/healthinfo/content.aspx?pageid=P01729
  8. national skin centre
    www.nsc.gov.sg/showpage.asp?id=314
  9. scleroderma program: raynaud phenomenon
    www.med.umich.edu/scleroderma/patients/raynauds.htm
  10. final diagnosis -- case 504
    path.upmc.edu/cases/case504/dx.html

Publications

  1. Assessment of abnormal blood flow and efficacy of treatment in patients with systemic sclerosis using a newly developed microwireless laser Doppler flowmeter and arm-raising test
    M Kido
    Department of Dermatology, Graduate School of Medical Sciences, Kyushu University, 3 1 1 Maidashi, Higashi ku, Fukuoka 812 8582, Japan
    Br J Dermatol 157:690-7
  2. Cold stimulus fingertip lacticemy test--an effective method to monitor acute therapeutic intervention on primary Raynaud's phenomenon and systemic sclerosis
    S M A Fontenelle
    Rheumatology Division, Escola Paulista de Medicina, Universidade Federal de São Paulo, SP 04023 062, Brazil
    Rheumatology (Oxford) 47:80-3
  3. Maximum blood flow and microvascular regulatory responses in systemic sclerosis
    H Gunawardena
    Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, BA1 1RL, UK
    Rheumatology (Oxford) 46:1079-82
  4. [Long-term effects of sildenafil in a patient with scleroderma-associated pulmonary hypertension and Raynaud's syndrome]
    S Rosenkranz
    Klinik III für Innere Medizin, Universität zu Koln
    Dtsch Med Wochenschr 129:1736-40
  5. Digital iontophoresis of vasoactive substances as measured by laser Doppler imaging--a non-invasive technique by which to measure microvascular dysfunction in Raynaud's phenomenon
    M E Anderson
    University of Manchester Rheumatic Diseases Centre, Hope Hospital, Salford, UK
    Rheumatology (Oxford) 43:986-91
  6. Digital vascular response to topical glyceryl trinitrate, as measured by laser Doppler imaging, in primary Raynaud's phenomenon and systemic sclerosis
    M E Anderson
    University of Manchester Rheumatic Diseases Centre, Hope Hospital, Salford M6 8HD, UK
    Rheumatology (Oxford) 41:324-8
  7. Ulnar artery involvement in systemic sclerosis (scleroderma)
    Marian H Taylor
    Department of Medicine, Medical University of South Carolina, Charleston 29425, USA
    J Rheumatol 29:102-6
  8. Determination of fingertip lacticemy before and after cold stimulus in patients with primary Raynaud's phenomenon and systemic sclerosis
    Mario L C Pucinelli
    J Rheumatol 29:1401-3
  9. [Therapy of systemic sclerosis]
    M Meurer
    Dermatologie am Universitätsklinikum Carl Gustav Carus, Technische Universität Dresden, Fetscherstrasse 74, 01307, Dresden, Germany
    Hautarzt 58:851-7
  10. Systemic sclerosis therapy with iloprost: a prospective observational study of 30 patients treated for a median of 3 years
    L Bettoni
    Servizio di Reumatologia ed Immunologia Clinica, Spedali Civili and University, I-25124 Brescia, Italy
    Clin Rheumatol 21:244-50

Scientific Experts

Detail Information

Webpages40 found, 30 most recent shown here

  1. research - division of rheumatology and clinical immunology at the university of pittsburgh department of medicine
    www.dept-med.pitt.edu/Rheum/research.html
  2. scleroderma
    www.chw.org/display/PPF/DocID/21658/router.asp
  3. scleroderma
    www.chw.org/display/PPF/DocID/21658/router.asp#1658
  4. scleroderma
    www.childrens.com/HealthLibrary/HealthLibContent.cfm?pageid= ...
  5. scleroderma program: classification of scleroderma
    www.med.umich.edu/scleroderma/patients/classification.htm
  6. retnet: disease table
    www.sph.uth.tmc.edu/retnet/disease.htm
  7. our physicians - health information
    www.memorialhealth.com/healthinfo/content.aspx?pageid=P01729
  8. national skin centre
    www.nsc.gov.sg/showpage.asp?id=314
  9. scleroderma program: raynaud phenomenon
    www.med.umich.edu/scleroderma/patients/raynauds.htm
  10. final diagnosis -- case 504
    path.upmc.edu/cases/case504/dx.html
  11. systemic lupus erythematosus (sle, or lupus) - high-risk pregnancy - health library - children's hospital of the king's daughters
    www.chkd.com/High_Risk_Pregnancy/autosle.asp
  12. systemic lupus erythematosus (sle, or lupus
    www.childrens.com/HealthLibrary/HealthLibContent.cfm?pageid= ...
  13. our physicians - health information
    www.memorialhealth.com/healthinfo/content.aspx?pageid=P02435
  14. hemolytic anemia
    www.health-disease.org/blood-disorders/hemolytic-anemia.htm
  15. raynaud disease
    lib.bioinfo.pl/meid:54144
  16. arthralgia
    lib.bioinfo.pl/meid:257053
  17. raynaud disease clinical resources
    wiregrassmc-dl.slis.ua.edu/clinical/cardiology/cardiovascula ...
  18. raynaud disease clinical resources
    dalemc-dl.slis.ua.edu/clinical/cardiology/cardiovascular/pvd ...
  19. raynaud disease clinical resources
    ahecpinebluff-dl.slis.ua.edu/clinical/cardiology/cardiovascu ...
  20. telangiectasis
    lib.bioinfo.pl/meid:52470
  21. raynaud's phenomenon ; seattle washington wa
    www.swedish.org/111808.cfm
  22. raynaud disease clinical resources
    baptistnashville-dl.slis.ua.edu/clinical/cardiology/cardiova ...
  23. raynaud disease clinical resources
    mtmc-dl.slis.ua.edu/clinical/cardiology/cardiovascular/pvd/a ...
  24. pulmonary embolism: medlineplus
    www.nlm.nih.gov/medlineplus/pulmonaryembolism.html
  25. raynaud disease clinical resources
    ruralnurseorganization-dl.slis.ua.edu/clinical/cardiology/ca ...
  26. raynaud disease patient/family resources
    baptistnashville-dl.slis.ua.edu/patientinfo/cardiology/cardi ...
  27. raynaud disease patient/family resources
    ahecpinebluff-dl.slis.ua.edu/patientinfo/cardiology/cardiova ...
  28. raynaud disease patient/family resources
    ruralnurseorganization-dl.slis.ua.edu/patientinfo/cardiology ...

Publications62

  1. Assessment of abnormal blood flow and efficacy of treatment in patients with systemic sclerosis using a newly developed microwireless laser Doppler flowmeter and arm-raising test
    M Kido
    Department of Dermatology, Graduate School of Medical Sciences, Kyushu University, 3 1 1 Maidashi, Higashi ku, Fukuoka 812 8582, Japan
    Br J Dermatol 157:690-7
    ....
  2. Cold stimulus fingertip lacticemy test--an effective method to monitor acute therapeutic intervention on primary Raynaud's phenomenon and systemic sclerosis
    S M A Fontenelle
    Rheumatology Division, Escola Paulista de Medicina, Universidade Federal de São Paulo, SP 04023 062, Brazil
    Rheumatology (Oxford) 47:80-3
    ..The CS-FTL test will enrich the armamentarium for investigation and clinical evaluation of conditions associated with RP...
  3. Maximum blood flow and microvascular regulatory responses in systemic sclerosis
    H Gunawardena
    Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, BA1 1RL, UK
    Rheumatology (Oxford) 46:1079-82
    ..SSc patients have abnormal microvascular regulatory responses compared with PRP and controls. This study also suggests that the degree of endothelial dysfunction may be related to the degree of peripheral vascular involvement...
  4. [Long-term effects of sildenafil in a patient with scleroderma-associated pulmonary hypertension and Raynaud's syndrome]
    S Rosenkranz
    Klinik III für Innere Medizin, Universität zu Koln
    Dtsch Med Wochenschr 129:1736-40
    ..CONCLUSION: PDE-5 inhibitors are efficacious in scleroderma-associated pulmonary hypertension and may also provide a new option in the treatment of Raynaud's disease...
  5. Digital iontophoresis of vasoactive substances as measured by laser Doppler imaging--a non-invasive technique by which to measure microvascular dysfunction in Raynaud's phenomenon
    M E Anderson
    University of Manchester Rheumatic Diseases Centre, Hope Hospital, Salford, UK
    Rheumatology (Oxford) 43:986-91
    ..If reproducibility is confirmed to be satisfactory, then these techniques could be used to examine disease progression over time and responsiveness to vasoactive treatment, thus facilitating clinical trials...
  6. Digital vascular response to topical glyceryl trinitrate, as measured by laser Doppler imaging, in primary Raynaud's phenomenon and systemic sclerosis
    M E Anderson
    University of Manchester Rheumatic Diseases Centre, Hope Hospital, Salford M6 8HD, UK
    Rheumatology (Oxford) 41:324-8
    ..As well as demonstrating the effectiveness of topical GTN in patients with PRP and LCSSc, this study illustrates the ability of laser Doppler imaging to quantify local vasodilatory effects...
  7. Ulnar artery involvement in systemic sclerosis (scleroderma)
    Marian H Taylor
    Department of Medicine, Medical University of South Carolina, Charleston 29425, USA
    J Rheumatol 29:102-6
    ..If suspected ulnar artery occlusion is confirmed by angiography or ultrasonography, ulnar artery revascularization with or without digital sympathectomy should be considered in patients who fail conventional medical therapy...
  8. Determination of fingertip lacticemy before and after cold stimulus in patients with primary Raynaud's phenomenon and systemic sclerosis
    Mario L C Pucinelli
    J Rheumatol 29:1401-3
    ..Further studies are warranted to test its possible clinical application in discriminating between patients with SSc and controls, as well as between patients with PPRP and PSRP...
  9. [Therapy of systemic sclerosis]
    M Meurer
    Dermatologie am Universitätsklinikum Carl Gustav Carus, Technische Universität Dresden, Fetscherstrasse 74, 01307, Dresden, Germany
    Hautarzt 58:851-7
    ..The current developments in organ-specific therapy are the main topic of the article. Finally, possibilities of disease-modifying drugs and value of HSCT are discussed...
  10. Systemic sclerosis therapy with iloprost: a prospective observational study of 30 patients treated for a median of 3 years
    L Bettoni
    Servizio di Reumatologia ed Immunologia Clinica, Spedali Civili and University, I-25124 Brescia, Italy
    Clin Rheumatol 21:244-50
    ..In conclusion, long-term therapy with iloprost in patients with SSc has a durable effectiveness on ischaemic ulcers and Raynaud's phenomenon, but it is not possible to conclude that the natural history of the disease was modified...
  11. Vasodilator iontophoresis a possible new therapy for digital ischaemia in systemic sclerosis?
    A K Murray
    Rheumatic Diseases Centre, Hope Hospital, Salford M6 8HD, UK
    Rheumatology (Oxford) 47:76-9
    ..Increasing iontophoresis time causes more sustained vasodilation. Further studies are indicated to investigate a possible therapeutic effect in patients with severe digital ischaemia...
  12. Oral sildenafil for the treatment of Raynaud's phenomenon and digital ulcers secondary to systemic sclerosis
    J Gore
    Ann Rheum Dis 64:1387
  13. Efficacy and tolerability of a selective alpha(2C)-adrenergic receptor blocker in recovery from cold-induced vasospasm in scleroderma patients: a single-center, double-blind, placebo-controlled, randomized crossover study
    Robert A Wise
    Johns Hopkins School of Medicine, Baltimore, Maryland 21224, USA
    Arthritis Rheum 50:3994-4001
    ....
  14. [Bosentan for treatment of active digital ulcers in patients with systemic sclerosis]
    David Launay
    Service de Médecine Interne, Centre National de Référence Atteintes Vasculaires de la Sclérodermie, Hôpital Claude Huriez, CHU de Lille, Université Lille 2
    Presse Med 35:587-92
    ..After a median follow-up of 24.3 months, only one recurrence was observed. Raynaud phenomenon improved in all but one patient...
  15. Infrared-monitored cold response in the assessment of Raynaud's phenomenon
    J Foerster
    Clinic for Dermatology, Charité, Berlin, Germany
    Clin Exp Dermatol 31:6-12
    ..As the duosensor is a simple stand-alone device requiring no supporting equipment and minimal personnel attention, it should allow RP activity monitoring even in clinical settings with minimal technical infrastructure...
  16. Digital periarterial sympathectomy for ischaemic digital pain and ulcers
    T A el Gammal
    Department of Orthopaedics, University of Iowa Hospitals and Clinics
    J Hand Surg Br 16:382-5
    ..Follow-up ranged from three to 16 months. After two weeks, all patients reported relief of pain and the ulcers were progressively healing. By three months, all ulcers had healed...
  17. [Manifestations of scleroderma at the hand--options for hand surgery in an interdisciplinary concept]
    A Daigeler
    Universitätsklinik für Plastische Chirurgie und Schwerbrandverletzte, Handchirurgiezentrum, Operatives Referenzzentrum für Gliedmassentumoren, Berufsgenossenschaftliche Kliniken Bergmannsheil, Bürkle de la Camp Platz 1, 44789 Bochum
    Handchir Mikrochir Plast Chir 39:128-34
    ..With reference to several cases seen at our institution, we propose an interdisciplinary treatment concept for acral manifestations of scleroderma...
  18. Digital thermal hyperaemia impairment does not relate to skin fibrosis or macrovascular disease in systemic sclerosis
    M Salvat-Melis
    INSERM ESPRI HP2 Laboratory, Grenoble Medical School, Grenoble University Hospital, Grenoble, France
    Rheumatology (Oxford) 45:1490-6
    ..Further studies are required to determine whether its impairment reflects a functional or structural microvascular damage...
  19. Comparison of thermography and laser Doppler imaging in the assessment of Raynaud's phenomenon
    Stuart Clark
    University of Manchester Rheumatic Diseases Centre, Hope Hospital, M6 8HD, Salford, UK
    Microvasc Res 66:73-6
    ..Therefore one technique cannot substitute for another...
  20. Infrared functional imaging applied to Raynaud's phenomenon
    Arcangelo Merla
    Department of Clinical Sciences and Bioimaging, University of Chieti
    IEEE Eng Med Biol Mag 21:73-9
  21. Successful treatment of digital ulcers in a scleroderma patient with continuous bilateral thoracic sympathetic block
    Kyung Ream Han
    Pain Clinic, Department of Anesthesiology and Pain Medicine, Ajou University Hospital, Suwon, Korea
    Pain Physician 11:91-6
    ..CONCLUSIONS: Continuous infusion of mepivacaine into the thoracic sympathetic ganglionic space led to the healing of the medically refractory gangrenous ulcer of the fingers in the patient with scleroderma...
  22. Limited microsurgical arteriolysis for complications of digital vasospasm
    S Tham
    New York University Medical Center, New York, USA
    J Hand Surg Br 22:359-61
    ..Following surgical microarteriolysis all digital ulcers healed completely. Severe digital ischaemic pain was significantly improved in all digits and completely resolved in 19 of 22 digits...
  23. The 'distal-dorsal difference': a thermographic parameter by which to differentiate between primary and secondary Raynaud's phenomenon
    M E Anderson
    University of Liverpool Adademic Rheumatology Unit, University Hospital Aintree, Liverpool, UK
    Rheumatology (Oxford) 46:533-8
    ..CONCLUSION: Parameters derived from thermography (incorporating both a heat and cold challenge) aid in the prediction of SSc in patients with RP...
  24. Colour duplex sonography of finger arteries in vasculitis and in systemic sclerosis
    W A Schmidt
    Medical Centre for Rheumotology Berlin Buch, Karower Str 11, 13125, Berlin, Germany
    Ann Rheum Dis 65:265-7
    ..In contrast, US in patients with systemic sclerosis is entirely different, delineating a smaller artery lumen, reduced pulsation, and thickened, slightly hyperechoic artery walls...
  25. Assessment of digital vascular structure and function in response to bosentan in patients with systemic sclerosis-related Raynaud's phenomenon
    T L Moore
    Rheumatology (Oxford) 46:363-4
  26. Treprostinil for the treatment of severe digital necrosis in systemic sclerosis
    Gregory Engel
    Division of Cardiovascular Medicine, Stanford University School of Medicine, Falk Cardiovascular Research Center, Stanford, CA 94305, USA
    Vasc Med 10:29-32
    ..This report provides an impressive example of an alternative, complementary indication for the use of treprostinil...
  27. [Digital flow exploration by color Doppler ultrasound in patients with Raynaud's disease or systemic sclerosis]
    C Cazalets
    Service de Médecine Interne, Hôpital Sud, Rennes
    J Mal Vasc 29:12-20
    ..No difference was found in skin thickness nor in the epidermal aspect between the two groups (table 5). CONCLUSION: Color Doppler ultrasound shows morphological and dynamic differences between RD and SS...
  28. Systemic sclerosis: an update for clinicians
    Ariane L Herrick
    Rheumatic Diseases Centre, Clinical Sciences Building, University of Manchester, Salford Royal NHS Foundation Trust, Salford M6 8HD
    Br J Hosp Med (Lond) 69:464-70
    ..This review will discuss diagnosis, subtyping, and the major clinical features and their management...
  29. [Sclerodermic acrosyndromes]
    Patrick H Carpentier
    Unité de médecine vasculaire Hôpital Michallon 38043 Grenoble
    Rev Prat 52:1891-5
    ..In the most severe cases, hospitalization in specialized centers is required, where customized physiotherapy and perfusions of prostaglandins or dextrans will be performed...
  30. Treatment of severe Raynaud's phenomenon with bosentan in a patient with systemic sclerosis
    J Dunne
    Rheumatology (Oxford) 45:911-2
  31. [Pathogenic mechanisms in systemic sclerosis and their therapeutical consequences. Part 2: treatment]
    J P Zuber
    Service d immunologie et d allergie Département de médecine CHUV, BH 18 707
    Rev Med Suisse 2:1058, 1060-6
    ..Prostaglandins, endothelin receptor antagonists and phosphodiesterase type 5 inhibitors permit to improve the treatment of the vascular complications (digital ulcerations, pulmonary arterial hypertension) of scleroderma...
  32. Management of Raynaud's phenomenon and digital ischemic lesions in scleroderma
    Laura K Hummers
    Division of Rheumatology, Johns Hopkins University, Baltimore, MD 21205, USA
    Rheum Dis Clin North Am 29:293-313
    ..Critical ischemia can cause deep tissue injury and digital loss. An aggressive approach to reversing an ischemic crisis is essential for preventing these severe events...
  33. Possible role of iloprost (stable analog of PG12) in promoting neoangiogenesis in systemic sclerosis
    P Faggioli
    Clin Exp Rheumatol 24:220-1
  34. Systemic scleroderma patients have improved skin perfusion after the transdermal application of PGE1 ethyl ester
    A Schlez
    Universitäts-Hautklinik, Eberhard-Karls-Universität, Tübingen
    Vasa 32:83-6
    ..6 +/- 2.0 per day (p < 0.05)). CONCLUSION: The transdermal application of prostaglandin E1 ethyl ester was shown to have a favourable effect on nutritive blood flow in the capillaries of the skin in systemic scleroderma patients...
  35. Diagnosis and management of scleroderma peripheral vascular disease
    Ariane Herrick
    Rheumatic Diseases Centre, University of Manchester, Salford Royal NHS Foundation Trust, Salford M6 8HD, UK
    Rheum Dis Clin North Am 34:89-114; vii
    ..New vasoactive treatments are currently being researched and older treatments revisited; therefore new approaches to therapy will likely be developed over the next 5 to 10 years...
  36. Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy
    Roland Fries
    Klinik für Innere Medizin III Kardiologie, Angiologie, Internistische Intensivmedizin, Universitätsklinikum des Saarlandes, Homburg Saar, Germany
    Circulation 112:2980-5
    ..53+/-0.09 versus 0.13+/-0.02 mm/s, P=0.0004). Two patients reported side effects leading to discontinuation of the study drug. CONCLUSIONS: Sildenafil is an effective and well-tolerated treatment in patients with Raynaud's phenomenon...
  37. [Systemic sclerosis--a challenge in rheumatology]
    P Saar
    Abt für Rheumatologie und klinische Immunologie, Lehrstuhl für Innere Medizin mit Schwerpunkt Rheumatologie der Justus Liebig Universität Giessen, Kerckhoff Klinik, Bad Nauheim
    Z Rheumatol 65:429-38; quiz 439-40
    ..Life expectancy is limited and depends predominantly on the extent of the organs involved. Therefore, it is essential to diagnose SSc early and to identify and closely monitor the organs involved...
  38. [Systemic sclerosis - diagnosis and classification]
    E Genth
    Rheumaklinik und Rheumaforschungsinstitut Aachen, Burtscheider Markt 24, 52066, Aachen, Germany
    Z Rheumatol 65:268-74
    ....
  39. Scleroderma-like nailfold capillaroscopic abnormalities are associated with anti-U1-RNP antibodies and Raynaud's phenomenon in SLE patients
    R N V Furtado
    Rheumatology Division, Escola Paulista de Medicina, Universidade Federal de São Paulo, Brazil
    Lupus 11:35-41
    ..The association of RP, anti-U1-RNP antibodies, and 'scleroderma-like' findings on nailfold capillaroscopy (SD-pattern) in patients with SLE may suggest a new SLE subset with subclinical features of systemic sclerosis...
  40. Nailfold video-capillaroscopy in systemic sclerosis
    M Cutolo
    Department of Internal Medicine, University of Genova, Viale Benedetto XV, 16132 Genova, Italy
    Z Rheumatol 63:457-62
    ..Further clinical and epidemiological studies, as well as a standardized and computerized quantitation of the observed damages are required...
  41. [Dysthyroidism and connective pathology]
    I Schachter
    UOC di Angiologia, Azienda Ospedaliera S. Giovanni-Addolorata, Roma
    Minerva Cardioangiol 54:811-4
    ..and connective pathology, both autoimmune diseases, presenting, sometimes, an early common symptom: the Raynaud phenomenon. METHOD: We studied 30 patients subdivided as follows: 18 affected by mixed connective pathology, 6 by ..
  42. [Antiphospholipid syndrome in patients with systemic connective tissue diseases]
    Dalia Unikiene
    Clinic of Rheumatology, Kaunas University of Medicine, Lithuania
    Medicina (Kaunas) 39:454-9
    ..There were significantly more cases of fibrotic heart valves (p=0.028), and thrombocytopenia (p=0.002), and livedo reticularis (p=0.058) in APS group...
  43. [Pulmonary arterial hypertension in connective tissue disease]
    V Cottin
    Service de Pneumologie, Centre de référence des maladies orphelines pulmonaires, Hôpital Louis Pradel, Hospices Civils de Lyon, Université de Lyon, UMR 754 INRA ENVL UCBL IFR128, Lyon, France
    Rev Mal Respir 23:13S61-72
    ..PERSPECTIVES: Respective indications of drugs and treatment associations need to be precised. CONCLUSION: The availability of efficacious treatments of PAH justifies its screening and early diagnosis in connective tissue diseases...
  44. Connective tissue disorders
    Lynn A Babin
    Cincinnati State Technical and Community College, OH, USA
    Dermatol Nurs 19:200, 207
  45. Iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis and the quality of life: a new therapeutic protocol
    G Milio
    Department of Internal Medicine and Cardiovascular Diseases, University of Palermo, Palermo, Italy
    Rheumatology (Oxford) 45:999-1004
    ..The protocol that we used, compared with others, not only has favourable clinical effects but also leads to a marked improvement in the quality of life...
  46. Thermographic and symptomatic effect of a single dose of sildenafil citrate on Raynaud's phenomenon in patients with systemic sclerosis: a potential treatment
    Namita Kumar
    J Rheumatol 33:1918-9
  47. Cardiovascular risk and prostanoids in systemic sclerosis
    M Colaci
    Chair and Rheumatology Unit, University of Modena e Reggio Emilia, Medical School Policlinico di Modena, Modena, Italy
    Clin Exp Rheumatol 26:333-6
    ..Since prostanoids represent the first choice treatment of the most severe scleroderma ischemic cutaneous lesions, cardiovascular risk should be carefully evaluated in all patients before therapy...
  48. [Systemic sclerosis]
    S Kleinert
    Schwerpunkt Rheumatologie und Klinische Immunologie, Medizinische Klinik und Poliklinik II, Universität Würzburg, Klinikstrasse 6 8, 97070, Würzburg, Germany
    Internist (Berl) 47:1051-61; quiz 1062
    ..In the acute state, immunosuppressive agents are needed in case of significant organ involvement. Vasodilative drugs are often used for the symptomatic treatment of Raynaud's phenomenon...
  49. Iloprost enhances portal flow velocity and volume in patients with systemic sclerosis
    Enrico Maria Zardi
    Interdisciplinary Center for Biomedical Research (CIR, Laboratory of Internal Medicine and Hepatology and Campus Bio-Medico University, School of Medicine, 00155 Roma, Italy
    In Vivo 20:377-80
    ..Iloprost improves the portal hemodynamics, favoring local microvascular patency, and its effectiveness may be safely monitored by using portal color Doppler ultrasonography...
  50. Comparable effects of sildenafil citrate and alprostadil on severe Raynaud's phenomenon in a patient with systemic sclerosis
    Y Kamata
    Clin Exp Dermatol 30:451
  51. [Iloprost therapy in systemic sclerosis]
    G Bali
    Universitätsklinik für Dermatologie und Venerologie, Karl-Franzens Universität Graz, Graz, Austria
    Hautarzt 54:845-51
    ..Although the effect of this treatment regimen should be proven in further long-term studies, we think that an intermittent continuous therapy with iloprost could result in an improvement or stabilization of systemic sclerosis...
  52. Association between capillaroscopy, haemorheological variables and plasma proteins in patients bearing Raynaud's phenomenon
    M I Spengler
    Departamento de Ciencias Fisiológicas, Cátedra de Física Biológica, Facultad de Ciencias Médicas, Universidad Nacional de Rosario, Santa Fe 3100, CP 2000, Rosario, Argentina
    Clin Hemorheol Microcirc 30:17-24
    ..Therefore, we can conclude that high levels of fibrinogen in Raynaud's phenomenon patients are associated with impaired skin microcirculation assessed by periungual capillaroscopy...
  53. Ischemic finger ulcer as a presenting symptom of systemic sclerosis
    Alexandra Balbir-Gurman
    Department of Rheumatology, Rambam Medical Center, Haifa, Israel
    Isr Med Assoc J 7:531-2
  54. Raynaud's phenomenon affecting the tongue of a patient with scleroderma
    M J Bridges
    Ann Rheum Dis 61:472
  55. Diffuse cutaneous systemic sclerosis treated with intravenous iloprost
    C Foti
    Clin Exp Dermatol 29:321-3
  56. Prognostic model based on nailfold capillaroscopy for identifying Raynaud's phenomenon patients at high risk for the development of a scleroderma spectrum disorder: PRINCE (prognostic index for nailfold capillaroscopic examination)
    Francesca Ingegnoli
    Department of Rheumatology, Instituto Gaetano Pini, University of Milan, Milan, Italy
    Arthritis Rheum 58:2174-82
    ..Our results suggest that this index could be used in clinical practice, and its further inclusion in prospective studies will undoubtedly help in exploring its potential in predicting treatment response...
  57. [Iloprost for the treatment of systemic sclerosis]
    Eric Hachulla
    Centre de référence des maladies auto immunes et maladies systémiques rares sclérodermie systémique, Service de Médecine Interne, Hôpital Claude Huriez, CHU, Université de Lille 2, F 59037 Lille Cedex, France
    Presse Med 37:831-9
    ..Intravenous iloprost improves kidney vasospasm in patients with scleroderma. The possible benefits of sequential intravenous iloprost on the natural course of scleroderma require further investigation...